The pharmaceutical distributor said the new company would be a differentiated medical surgical supply and solutions business.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Besides Wall Street's top -and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) closed at $712.79 in the latest trading session, marking a +0.78% move from the prior day.
McKesson (MCK) reachead $699.73 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the latest trading session, McKesson (MCK) closed at $695.17, marking a +1.86% move from the previous day.
In the most recent trading session, McKesson (MCK) closed at $694.70, indicating a +0.27% shift from the previous trading day.
Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.
McKesson (MCK) closed the most recent trading day at $679.33, moving +1.13% from the previous trading session.